New

Meeting videos
HealthInnovationIn vitro
Helpathon #8 – Can you help Margot?
Margot Beukers is the LymphChip program manager. Can you help Margot bring the field forward by sharing your experience with animal-free alternatives for Foetal Calf Serum and Matrigel?
Click on the link in the video to sign up and read more information on this Helpathon on the website (https://www.helpathonhotel.org/coming-up).

Meeting videos
HealthInnovationIn vitro
Helpathon #8 – Can you help Jasper?
Jasper Koning is doing research on skin diseases. He believes it must be possible to find an alternative to Foetal Calf Serum to grow immune cells. Can you help him find alternatives to Foetal Calf Serum so he can build human models animal free? Jasper is especially looking for researchers with practical experience in applying alternatives. He did some trials himself with mixed results.
Click on the link in the video to sign up and read more information on this Helpathon on the website (https://www.helpathonhotel.org/coming-up).

Meeting videos
HealthInnovationIn vitro
Helpathon #8 – Can you help Germaine?
Germaine Aalderink is investigating the uptake of lipids travelling from the gut into the lymphatic system and further explore the merits of this alternative drug intake strategy. Can you help Germaine make an intestinal and lymphatic model with an alternative for Matrigel that is animal-free? She wants to know what components are essential in each phase of intestinal development and is interested in both the positive and negative experiences of other researchers with the use of alternatives for Matrigel.
Click on the link in the video to sign up and read more information on this Helpathon on the website (https://www.helpathonhotel.org/coming-up).

Innovation examples
HealthInnovationIn vitro
Using skin and mucosa models to replace animal testing
The skin and mucosa are important tissues that differ between species in health and disease. The group of Sue Gibbs works on the development of advanced in vitro models that mimic these two tissues, specialising in immunity models and organ-on-a-chip technologies. They use skin models to study for example melanoma, skin allergies, eczema, burns and healing wounds. Dental models are used for the safety of materials used in dentistry, for example to test the quality of the implant and false tooth when it comes to attaching to the soft tissue. Their ambition is to expand into the field of multi-organ technology to make even more relevant models for the human skin and mucosa.
Click on the link in the video to watch more or read the interview with Sue he[https://vu.nl/en/research/more-about/using-skin-and-mucosa-models-to-replace-animal-testing]re.

Innovation examples
HealthInnovationData
Using data and computational modelling in biomedical research
Bioinformatics and systems biology hold great promise to translate the wealth of biological data into meaningful knowledge about human health and disease. The group of Bas Teusink helps biologists to deal with high throughput data, for example metabolomics (how cell metabolism works) and proteomics (how protein networks work) from patient material or cell cultures. This can help to better understand disease mechanisms and aid drug targeting or personalised medicine. In the future, combining data from different models (in vitro, in vivo and human data) could become a digital model of humans, or a “ digital twin”.
Click on the link in the video to watch more or read the interview with Bas (and Jaap Heringa) he[https://vu.nl/en/research/more-about/using-data-and-computational-modelling-in-biomedical-research]re.

Innovation examples
HealthInnovationIn vitro
Treating genetic heart disease using engineered heart tissue
Some heart disease are caused by a gene mutation in the cardiac muscle cells. People with this genetic disease are affected it between the ages of 20 and 40, and there is no preventative treatment for this. The group of Jolanda van der Velden works on the development of engineered heart tissue made from human stem cells to unravel disease mechanisms and test drugs to treat the disease. They use different kinds of stem-cell-based cultures. 2D cell cultures are useful to test a large number of candidate drugs, while patient-derived stem cells that are differentiated in heart cells can help to get detailed understanding of the disease and test the most promising treatments.
Click on the link in the video to watch more or read the interview with Jolanda here (https://vu.nl/en/research/more-about/treating-genetic-heart-disease-using-engineered-heart-tissue).

Innovation examples
HealthInnovationIn vitro
Using human organoid technology to treat viral infections in children
Viral infection in (very young) children can be detrimental to their neurological health. The mechanisms of some viruses work very differently in children compared with adults, which is not well understood yet. The research group of Dasja Pajkrt studies viral infections in children from the clinic by using human-derived organoids. They focus on three groups of viruses that can severely affect children: picornaviruses (responsible for illnesses like meningo-encephalitis and sepsis), cytomegalovirus (which can cause severe disabilities in children born with this virus) and HIV. The human-derived organoids or multi-organ systems allow for detailed mechanistic analysis of the disease and possible treatments that can be brought back to the clinic.
Click on the link in the video to watch more or read the interview with Dasja here (https://vu.nl/en/research/more-about/using-human-organoid-technology-to-treat-viral-infections-in-children).

Innovation examples
HealthInnovationIn vitro
Tumor-on-chips to study delivery of protein therapeutics
Valentina is a PhD candidate at the Department of Biochemistry at Radboudumc. Her research focuses on developing and applying organ-on-chip technologies, such as tumor-on-a-chip systems, to study the tissue-specific and cytosolic delivery of protein therapeutics. Valentina's research has also aimed at bridging the gap between engineers and biologists, promoting the use of microfluidic organ-on-chip technologies to answer more relevant biological questions. One example of this is the development of a mathematical model that could be applied to study drug delivery and diffusion in a tumor-on-a-chip system and to extrapolate possible outcomes of the delivery of therapeutic proteins to tumors in the human body. Another collaboration led to the development of a tumor-on-a-chip where hypoxic conditions can be replicated and investigated, and where the targeting of specific hypoxia markers in tumor cells can be investigated.

Innovation examples
ToxicologyInnovationIn vitro
Stem cell differentiation assays for animal-free developmental neurotoxicity assessment
Victoria de Leeuw was a PhD candidate in the research group of prof. dr. Aldert Piersma at the RIVM and Institute for Risk Assessment Sciences at Utrecht University. Piersma's lab studies the effects of compounds on development of the embryo during pregnancy with, among other techniques, stem cell cultures. The project of Victoria was aimed to differentiate embryonic stem cells of mouse and human origin into neuronal and glial cells, which could mimic parts of differentiation as seen during embryonic brain development. These models were able to show some of the known toxic mechanisms induced by these compounds, congruent with what they we hypothesised to mimic. This provides mechanistic information into how chemical compounds can be toxic to brain development. Therefore, these two stem cell assays make a useful contribution to the animal-free assessment of developmental neurotoxicity potential of compounds.
Victoria is nominated for the Hugo van Poelgeest prize 2022 for excellent research to replace animal testing.

Innovation examples
HealthInnovationIn vitro
Immortalized human cells to model atrial fibrillation in vitro
Niels Harlaar is a PhD Candidate at the Laboratory of Experimental Cardiology at the Leiden University Medical Center. Here, under the supervison of prof. dr. D.A. Pijnappels and dr. A.A.F. de Vries, he focusses on the conditional immortalization of human atrial cardiomyocytes for (among many other applications) in vitro modelling of atrial fibrillation. He has successfully generated, characterized and applied this technique of these conditionally immortalized human atrial myocyte lines to model atrial fibrillation in vitro.
Niels is nominated for the Hugo van Poelgeest prize 2022 for excellent research to replace animal testing.
Click here (https://hartlongcentrum.nl/research/laboratory-of-experimental-cardiology/) for more information on the Laboratory of Experimental Cardiology.

Meeting videos
Helpathon #7 - Can you help Jesmond and Duco?
Can you help Jesmond Dalli, Professor at Barts, the London School of Medicine and Dentistry and Queen Mary University of London and Duco Koenis, Post-Doctoral Fellow in his team, to identify animal free research methods to discover novel drug targets for resolving inflammation in rheumatoid arthritis and bacterial infections? Join Helpathon #7 – first of its kind as it will take place in the UK, on 10-11th of October 2022.

Meeting videos
Helpathon #6 - Can you help Sue?
The Helpathon team is professionalising their #animalfreeinnovation helpathon practice. After two days of hard work the question how the Helpathon Hotel sould look like took shape. This friendly, disruptive, co-creative approach has proven to create new networks, new insights and in the most tangible way new animal free research projects. We are proceeding under the new name of #helpathonhotel.